Radicava ORS (edaravone) vs Relyvrio (sodium phenylbutyrate and taurursodiol)
Radicava ORS (edaravone) vs Relyvrio (sodium phenylbutyrate and taurursodiol)
Radicava ORS (edaravone) is an oral suspension formulation of edaravone, an antioxidant that helps to slow the decline of physical function in patients with amyotrophic lateral sclerosis (ALS) by reducing oxidative stress. Relyvrio (sodium phenylbutyrate and taurursodiol) is a combination drug that works through different mechanisms, potentially reducing neuronal cell death and improving mitochondrial function, which can also slow disease progression in ALS. When deciding between the two, patients should consider factors such as the route of administration, potential side effects, the mechanism of action, and any specific recommendations from their healthcare provider based on their individual health profile and disease progression.
Difference between Radicava ORS and Relyvrio
| Metric | Radicava ORS (edaravone) | Relyvrio (sodium phenylbutyrate and taurursodiol) |
|---|---|---|
| Generic name | Edaravone | Sodium phenylbutyrate and Taurursodiol |
| Indications | Amyotrophic lateral sclerosis (ALS) | Amyotrophic lateral sclerosis (ALS) |
| Mechanism of action | Free radical scavenger | Neuroprotective and antiapoptotic effects |
| Brand names | Radicava, Radicut | Relyvrio |
| Administrative route | Oral suspension | Oral |
| Side effects | Bruising, gait disturbance, headache | Diarrhea, abdominal pain, nausea |
| Contraindications | Hypersensitivity to edaravone or any of the excipients | Hypersensitivity to any component of the product |
| Drug class | Free radical scavenger | Combination of amino acid derivative and bile acid derivative |
| Manufacturer | Mitsubishi Tanabe Pharma | Amylyx Pharmaceuticals |
Efficacy
Efficacy of Radicava ORS (Edaravone) for ALS
Radicava ORS (edaravone) is an oral suspension formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). Edaravone is believed to work by relieving oxidative stress, which may play a role in the nerve cell damage associated with ALS. Clinical trials have demonstrated that Radicava ORS can slow the decline in physical function in ALS patients. The pivotal trial that led to its approval showed a statistically significant reduction in the rate of decline in the ALS Functional Rating Scale-Revised (ALSFRS-R) score in individuals treated with edaravone compared to placebo.
However, it is important to note that while Radicava ORS has been shown to slow the progression of ALS, it is not a cure for the disease. The efficacy of edaravone may vary among patients, and not all patients may respond to treatment. Additionally, the long-term benefits and optimal duration of treatment with Radicava ORS are still subjects of ongoing research.
Efficacy of Relyvrio (Sodium Phenylbutyrate and Taurursodiol) for ALS
Relyvrio, a combination of sodium phenylbutyrate and taurursodiol, is another medication approved by the FDA for the treatment of ALS. The combination of these two compounds is thought to help protect nerve cells from stress and improve mitochondrial function. Clinical trials have shown that Relyvrio can slow the decline in ALS patients' clinical assessment of daily functioning as measured by the ALSFRS-R score. The CENTAUR trial, which was instrumental in the approval of Relyvrio, demonstrated that patients taking the drug experienced a slower rate of functional decline compared to those taking a placebo.
Similar to Radicava ORS, Relyvrio is not a cure for ALS, but it represents another treatment option that can potentially improve the quality of life for patients by slowing disease progression. The combination of sodium phenylbutyrate and taurursodiol has also been associated with increased survival in ALS patients, according to the results of the CENTAUR trial. As with all medications, the response to Relyvrio may vary among individuals, and further studies are ongoing to better understand its long-term efficacy and safety profile.
Regulatory Agency Approvals
Radicava ORS
-
Food and Drug Administration (FDA), USA
-
Health Canada
Relyvrio
-
Food and Drug Administration (FDA), USA
Access Radicava ORS or Relyvrio today
If Radicava ORS or Relyvrio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us